Synaptogenix Past Earnings Performance
Past criteria checks 0/6
Synaptogenix has been growing earnings at an average annual rate of 15%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
15.0%
Earnings growth rate
68.6%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | -62.7% |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
We Think Synaptogenix (NASDAQ:SNPX) Can Afford To Drive Business Growth
Sep 20
Companies Like Synaptogenix (NASDAQ:SNPX) Are In A Position To Invest In Growth
May 10Synaptogenix: High-Risk High-Reward For Potential Alzheimer's Disease Treatment
Nov 17Synaptogenix (NASDAQ:SNPX) Is In A Good Position To Deliver On Growth Plans
Oct 05Synaptogenix: The Next Big Thing In Alzheimer's
Jun 16Synaptogenix provides update on phase 2b Alzheimer's disease trial
Jun 09We're Keeping An Eye On Synaptogenix's (NASDAQ:SNPX) Cash Burn Rate
Jun 09Revenue & Expenses Breakdown
How Synaptogenix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -9 | 5 | 2 |
| 30 Jun 24 | 0 | -3 | 5 | 2 |
| 31 Mar 24 | 0 | -12 | 5 | 2 |
| 31 Dec 23 | 0 | -14 | 6 | 2 |
| 30 Sep 23 | 0 | -8 | 9 | 3 |
| 30 Jun 23 | 0 | -11 | 10 | 4 |
| 31 Mar 23 | 0 | -4 | 10 | 6 |
| 31 Dec 22 | 0 | -6 | 10 | 6 |
| 30 Sep 22 | 0 | -14 | 8 | 6 |
| 30 Jun 22 | 0 | -14 | 9 | 6 |
| 31 Mar 22 | 0 | -13 | 8 | 5 |
| 31 Dec 21 | 0 | -13 | 8 | 4 |
| 30 Sep 21 | 0 | -14 | 7 | 4 |
| 30 Jun 21 | 0 | -15 | 7 | 4 |
| 31 Mar 21 | 0 | -16 | 8 | 4 |
| 31 Dec 20 | 0 | -15 | 8 | 3 |
| 30 Sep 20 | 0 | -12 | 8 | 3 |
Quality Earnings: SNPX is currently unprofitable.
Growing Profit Margin: SNPX is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: SNPX is unprofitable, but has reduced losses over the past 5 years at a rate of 15% per year.
Accelerating Growth: Unable to compare SNPX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: SNPX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (16.6%).
Return on Equity
High ROE: SNPX has a negative Return on Equity (-62.65%), as it is currently unprofitable.